Rhabdomyosarcomas (RMSs) are one of the most common solid tumor of childhood. Rhabdomyosarcoma (RMS) cells fail to both complete the skeletal muscle differentiation program and irreversibly exit the cell cycle as a consequence of an active repression exerted on the muscle-promoting factor MyoD. Myostatin is a negative regulator of normal muscle growth, we have thus studied its possible role in RMS cells. Here, we present evidence that overexpression of myostatin is a common feature of RMS since both subtypes of RMS (embryonal RD and alveolar Rh30 cells) express high levels of myostatin when compared to nontumoral skeletal muscle cells. Interestingly, we found that inactivation of myostatin through overexpression of antisense myostatin or of follistatin (a myostatin antagonist) constructs enhanced differentiation of RD cells. In addition, RD and Rh30 cells treated with blocking antimyostatin antibodies progress into the myogenic terminal differentiation program. Finally, our results suggest that high levels of myostatin could impair MyoD function in RMS cells. These results show that an autocrine myostatin loop contributes to maintain RMS cells in an undifferentiating stage and suggest that new therapeutic approaches could be exploited for the treatment of RMS based on inactivation of myostatin protein.
Introduction
Rhabdomyosarcomas (RMSs) are one of the most common solid tumors of childhood, thought to arise from myogenic precursor cells. Even though these tumors express a number of muscle-specific proteins, they fail to complete the myogenic differentiation program (Tonin et al., 1991) . This absence of differentiation is most likely the consequence of an active repression exerted on the muscle-promoting factor MyoD. Although it is able to bind DNA, MyoD cannot effectively induce muscle gene transcription in the rhabdomyosarcoma (RMS) cells. Moreover, ectopic expression of MyoD is not sufficient to induce the myogenic program. These myogenic defects are complemented in heterokaryons between the tumor cells and fibroblasts, suggesting that MyoD deficiency could be due either to the absence of a positive regulator or to the presence of an inhibitor (Tapscott et al., 1993) . Thus, these observations suggest that mechanisms preventing transactivation of muscle-specific genes by MyoD in RMS must then exist and may result in the generation of RMS tumors.
The lack of differentiation in RMS cells has been correlated with multiple genetic alterations. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar RMS can inhibit MyoD activity (Galili et al., 1993; Shapiro et al., 1993; Epstein et al., 1995) . Overexpression of inhibitors of muscle differentiation have been reported in RMSs such as MDM2, ATR, Ras, Myc, c-Met and Twist (for a review see Merlino and Helman, 1999) . Inactivation of specific signaling systems may also constitute an important mechanism whereby differentiation is disrupted in RMS. Indeed, it has recently been shown that the p38 MAPK pathway was defective in RMS cells and that forced activation of p38 by its upstream kinase MKK6 can restore a partial myogenic program in these cells (Puri et al., 2000) . These reports provide evidence that multiple mechanisms, either alone or in combination, may underlie the failure of RMS to differentiate. These tumors therefore constitute an interesting model to identify novel members of pathways which are crucial for myogenic differentiation.
Of all the different growth factors regulating the development and growth of skeletal muscle, our attention has focused on the recently discovered new TGFb family member myostatin, also known as growth/ differentiating factor-8 . This factor is expressed in skeletal muscle tissues from the period of embryogenesis to adulthood and functions as a negative regulator of tissue growth . The biological function of myostatin comes from the phenotype of myostatin-deficient animals. Mice with null mutations of the myostatin gene have increased muscle mass resulting from an increased number and size of muscle fiber. Mutations of the myostatin gene have been found in double-muscle cattle (Grobet et al., 1997; Kambadur et al., 1997; . Recent studies have revealed that myostatin antagonists, such as follistatin and the myostatin propeptide may be effective agents to enhance muscle mass in a variety of setting (Lee and McPherron, 2001; Zimmers et al., 2002) . Furthermore, two research groups reported that blocking the action of myostatin could treat Duchenne muscular dystrophy and perhaps other muscle-wasting diseases by increasing muscle mass and thus muscle strength (Bogdanovich et al., 2002; Wagner et al., 2002) . Along with its potential to control muscle mass, in vitro studies have shown that myostatin inhibits both myoblast proliferation and differentiation (Thomas et al., 2000; Rios et al., 2001 Rios et al., , 2002 Taylor et al., 2001; Langley et al., 2002) .
Based on these observations, we have considered the possibility that myostatin may contribute to the nonmuscle-differentiating phenotype in RMSs. We compared RMS cell lines (RD and Rh30) and several myogenic cells (C2, L6 and clonal human primary myoblasts) for the expression of myostatin. Here, we report that RD and Rh30 cells express high levels of myostatin mRNA and produce high levels of secreted myostatin protein compared to human primary myoblasts, whereas no expression of myostatin was detected in C2 and L6 cells. We also observed that myostatin levels decrease in normal human myoblasts cultured in differentiation medium, while under these conditions they remain elevated in both RD and Rh30 cells. Moreover, TPA-induced differentiation of RD cells correlates with a decrease in myostatin production. These data suggested an involvement of myostatin in the nondifferentiating phenotype of RMS cells. We, therefore, examined the role of myostatin in this system model and demonstrated that blockade of myostatin production by means of antisense gene transfection or overexpression of follistatin enhances the ability of RD cells to differentiate. Finally, treatment with antimyostatin antibodies also enhanced differentiation of RD and Rh30 rhabdomyoblasts. Our results indicate that there was no variation in MyoD expression in RMS cells after repression of myostatin by overexpression of antisense myostatin construct or addition of antimyostatin antibodies to the culture medium. Furthermore, when overexpressed in 10T1/2 cells, myostatin inhibited muscle-promoting activity of the transcription factor MyoD while in RD and Rh30 cells inhibition of myostatin by overexpression of follistatin or addition of antimyostatin antibodies improves the activity of MyoD, suggesting a mechanism by which myostatin exerts its antidifferentiation action in RMS cells. Taken together, these results show that autocrine myostatin contributes to the lack of differentiation in the RMS cell lines.
Results

RMS cell lines express high levels of myostatin
To investigate the possible role of myostatin in RMS, we first compared expression at the mRNA level of the myostatin gene between various myogenic cells including rat L6 myoblasts, mouse C2 myoblasts, human embryonal (RD) and alveolar (Rh30) rhabdomyoblasts and cloned human myoblasts (CHM). Northern blot experiments (Figure 1a) showed that myostatin mRNA (3.1 kb) was expressed at the proliferating myoblast stage in both cloned human myoblasts, RD and Rh30 cells, whereas it is undetectable in C2 and L6 myoblasts. It is of note that Artaza et al. (2002) reported that they failed to detect endogenous myostatin mRNA in either total or poly A þ selected RNA from C2 myoblasts and myotube cultures by Northern blot analysis. These authors and others (Rios et al., 2001) only successfully determined the levels of endogenous myostatin mRNA expression by semiquantitative RT-PCR analysis, which suggests that C2 cells express weak levels of myostatin. Moreover, RMS cells express more myostatin mRNA as compared to cloned human myoblasts (Figure 1a and c) . Collectively, these data reveal that RMS cells express high levels of myostatin.
Myostatin expression is dependent on the differentiation status
We then examined whether myostatin expression is dependent on cell culture conditions and/or the differentiation status. To address this question, CHM, RD and Rh30 cells were grown to a relatively high density (about 50-80% of confluence) in a growth medium (10% FCS) (GM), then induced to differentiate in a lowserum medium (2% FCS) (DM). As shown in Figure 1b , with the cloned human myoblasts which undergo terminal differentiation on transfer from the GM to the differentiation medium (DM), the level of myostatin mRNA decreases in DM (about eightfold), while with RD and Rh30 cells which have a poor capacity to differentiate, the high level of myostatin mRNA is maintained by culture in DM (reduction about 1.5-fold) (Figure 1b and c) . To verify that myostatin mRNA expression is accompanied by a secretion of the protein, in a parallel experiment, proteins extracted from a serum-free medium of cloned human myoblasts, as well as from a serum-free medium of the RMS cell lines RD and Rh30, cultured as above, were analysed by Western blot using a polyclonal antimyostatin antibody which recognizes the precursor (molecular mass of about 52 kDa) and processed (molecular mass of about 15 kDa) forms of the myostatin protein, in agreement with data obtained by . We found that RMS cell lines and cloned human myoblasts expressed both unprocessed and active forms of myostatin and that the changes in the pool of myostatin protein appear to reflect the fluctuations in myostatin mRNA level for each cell type (Figure 1d ). Note that expression of myostatin is markedly decreased in Bouche et al. (1993) . For this purpose, RD cells cultured in growth medium were treated 1 day after plating with fresh medium containing or not containing TPA (100 nM) and differentiation was monitored by Western blot and immunofluorescence analysis using antibodies directed against two muscle markers, namely myosin-heavy chain (MHC) and troponin T. Consistent with the results of Bouche et al. (1993) , we found that TPA enhances RD cell differentiation, as demonstrated by the increase of troponin T positive cells (Figure 2a ) and the accumulation of the myosin-heavy chain (MHC) muscle marker in TPAtreated vs untreated RD cells (Figure 2b ). Furthermore, under the same experimental conditions, we analysed the level of myostatin secreted. As shown in Figure 2c , the pool of myostatin protein is consistently lower in serum-free medium from TPA-treated vs untreated cells. These data indicate that the level of the myostatin protein declines as RD cell differentiation proceeds. Taken together, these data indicate an inverse correlation between the level of myostatin expression and the ability of myogenic cells to differentiate and thereby might suggest an involvement of myostatin in blocking RMS differentiation.
RD cells secrete active myostatin
As higher levels of myostatin mRNA and protein expression were observed in RD cells, they were chosen for subsequent cell analysis. To investigate the role of myostatin in the RD differentiation system, the RD cell line was stably cotransfected with a myostatin antisense construct (pSG5AMstn) along with pSV2neo as selection marker. Control RD clones stably cotransfected with pSG5 plasmid without insert plus pSV2neo (RDneo) were established in parallel. Several stable cell populations were further characterized and tested for their myostatin expression. As shown in Figure 3a , serum-free medium of two representative colonies, referred to as RDAMstn1 and RDAMstn2 for RD Anti-Myostatin 1 and 2, contain weaker levels of myostatin than serum-free medium of RD or RDneo cells. It should be noted that RD or RDneo cells have comparable levels of myostatin.
Given the ability of myostatin to inhibit C2 cell proliferation (Thomas et al., 2000; Rios et al., 2001; Taylor et al., 2001) , we next compared the effects of conditioned medium from RD, RDneo, RDAMstn1 and RDAMstn2 cells on the proliferation of C2 cells. C2 myoblasts were therefore seeded in growth medium (GM) or in conditioned medium, either by RD, RDneo, RDAMstn1 or RDAMsm2 cells, for 4 days; cells were harvested and counted each day (see Materials and methods). We found that both conditioned medium from RD and RDneo cells inhibited proliferation of C2 cells, while conditioned medium from RDAMstn1 or RDAMstn2 cells did not significantly prevent proliferation of C2 cells (Figure 3b ). Note that the RDAMstn1 conditioned medium remains more efficient in inhibiting proliferation than the RDAMstn2 conditioned medium, a fact that is reflected in the level of the myostatin protein. Thus, the more the level of myostatin is high in the conditioned medium, the greater the antiproliferative effect. These data demonstrate that specific downregulation of the myostatin protein in RD cells by antisense strategy results in a lesser antiproliferative effect of their conditioned medium. These data also indicate that myostatin secreted by RD cells is biologically active, consistent with the presence of the processed active form of myostatin (see Figure 1d ).
Inhibition of myostatin production and activity reactivates myogenic differentiation in RD cells
The inverse correlation between the level of myostatin expression and the ability of myogenic cells to differentiate led us to study the consequences of the inhibition of myostatin production in RD cells. We thus examined the RD myostatin antisense cell lines (including RDneo as well as RDAMstn1 and RDAMstn2) with respect to their proliferation and differentiation properties. For this purpose, RDAMstn 1 and 2 and RDneo control cells were thus plated in growth medium (GM) and cell clones. Cells were induced to differentiate in a lowserum medium for 4 days and differentiation was monitored by immunofluorescence analysis, using an anti-troponin T antibody ( Figure 4b ). As expected, the ability of RDneo cells to differentiate terminally is almost nonexistent, as shown by the weak expression of troponin T with 5-10% of the cultured cells undergoing differentiation after 4 days of culture in DM. By contrast, the RD antisense transfectants exhibited an induction of differentiation ranging from 20 to 40% of the cells differentiated at day 4. Note that this induction of differentiation is more efficient in RDAMstn2 cells. To control whether these cells displaying features of differentiation have undergone withdrawal from the cell cycle, we monitored the expression of cyclin A a marker of cell proliferation. As shown in Figure 4b , when cultured in GM the proportion of cells expressing cyclin A is greater in RDAMstn cells than in control RDneo cells. When subsequently placed in differentiation medium (DM) for 4 days, the percentage of RDAMstn cells positive for cyclin A markedly decreases indicating that these differentiating cells have withdrawn from the cell cycle. In contrast, the proportion of cells expressing cyclin A in DM remains elevated in control RDneo cells, which is consistent with the inability of RD cells to growth arrest when cultured in DM (Knudsen et al., 1998) . A Western blot analysis confirmed the inhibition of cyclin A which is followed by the expression of specific differentiation markers: myogenin, troponin T and myosin-heavy chain (MHC) in stable RD antisense clones (Figure 4c ). These results indicate that downregulation of the myostatin protein can restore normal cell cycle withdrawal and override the differentiation block in RD cells. As reported by Langley et al. (2002) inhibition of differentiation by myostatin in normal myoblasts is associated with decreased expression of MyoD. However, our analysis of MyoD showed that its expression was not modified between RD neo and RD myostatin antisense cell lines (Figure 4c ).
To investigate whether inhibition of myostatin activity also enhances RD cell differentiation, we examined the effect of the overexpression of follistatin, which has been shown to be capable of blocking the activity of myostatin (Lee and McPherron, 2001; Zimmers et al., 2002) . We first tested the antagonist activity of follistatin following transient transfection into RD cells with the use of the pGL3-(CAGA) 12 luciferase reporter assay (see Materials and methods) (Figure 5a ). This reporter gene assay has been shown to reflect myostatin activity (Thies et al., 2001; Zimmers et al., 2002) . As shown in Figure 5a , the reporter luciferase activity is activated in RD cells. However, we noted an inhibition of this luciferase activity when follistatin was cotransfected, suggesting an inhibition of myostatin activity. We next established stably follistatin expressing RD cells by transfecting pcDNAlneo containing the mouse follistatin (see Materials and methods). Control cells were transfected with pcDNAlneo without insert. Several stably transfected colonies were selected and further characterized. These colonies expressed different levels of follistatin as determined by Northern blotting (Figure 5b ). Myogenic differentiation in these cell lines was tested by immunofluorescence analysis. Cells were induced to differentiate in a lowserum medium for 4 days, then immunostained for troponin T and cyclin A. As shown in Figure 5c , cells expressing follistatin (RDFoll and 2) depicted an induction of troponin T expression compared to control RDneo cells whereas they concomitantly exhibited a decrease in cyclin A expression attesting that these cells have both exited cell cycle and activated muscle gene expression. Furthermore, in the same conditions, we compared the differentiation kinetics between RDneo and RD Follistatin cell lines by Western blotting analysis for expression of cyclin A and of two markers of muscle differentiation, myogenin and troponin T (Figure 5d ). Again, these experiments clearly demonstrate that overexpression of follistatin restored terminal differentiation of RD cells as follistatin transfected RD cells expressed high levels of myogenin and troponin T protein whereas RDneo control cells did not. The induction of muscle-specific markers appears correlated with the reduction of cyclin A in RD Follistatin cell lines. Collectively, these data indicate that overexpression of follistatin, an antagonist of myostatin, also enhances RD cell differentiation and restores normal cell cycle withdrawal.
Treatments with antimyostatin antibodies enhance differentiation capacity of RMS RD and Rh30 cells
Lastly, we investigated whether targeted inhibition of myostatin, through addition of blocking antibodies, could enhance terminal differentiation of RMS cells. We first tested the capacity of these antibodies to antagonize myostatin activity. For this purpose, RD and Rh30 cells were transfected with the pGL3-(CAGA) 12 luciferase reporter gene in presence of polyclonal antibodies directed against the COOH-terminal myostatin peptide or preimmune serum as control. We observed that addition of myostatin antibodies induced a two-to threefold reduction of the reporter luciferase activity indicating an inhibition of myostatin activity (Figure 6a ). Then, RD and Rh30 cells were induced to differentiate in low serum medium supplemented with antimyostatin antibodies or preimmune serum as control for 4 days, and the expression of troponin T was assessed by immunofluorescence analysis. We observed that culture in presence of antimyostatin antibodies induced the formation of multinucleated cells both in RD and Rh30 cells, which expressed troponin T ( Figure 6b ). As confirmed by Western blotting analysis, RD and Rh30 cells treated with antimyostatin antibodies displayed increased levels of muscle-specific markers such as myogenin, troponin T and MHC as compared with RD and Rh30 cells incubated with preimmune serum (Figure 6c ). Interestingly, a nonblocking antimyostatin antibody raised against the N-terminus, which does not bind the active form of myostatin, failed to induce RD and Rh30 cell differentiation (data not shown). Moreover, the level of cyclin A was reduced in presence of antimyostatin antibodies, attesting that these cells have withdrawn
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Myostatin impedes MyoD activity to transactivate skeletal muscle genes
In skeletal muscle cells, differentiation is tightly controlled by the transcription factor MyoD which binds to a consensus DNA sequence, the E-box, present in most muscle promoters (Weintraub et al., 1991) . To determine whether myostatin exerts its inhibitory effect on muscle differentiation by targeting MyoD activity, we used classical transactivation assays. First, we used a reporter plasmid containing the E-box DNA-binding sites from the a-subunit promoter of a mouse acetylcholine receptor (Ebox-tk-CAT) that mediates MyoD differentiation-dependent activity in cultured skeletal muscle cells (Piette et al., 1990) . RD antisense myostatin, RD Follistatin and their respective control RDneo cells were transfected with the Ebox-tk-CAT construct. In each case, b-galactosidase expression plasmid was cotransfected as an internal control for After transfection, cells were placed in a proliferation medium for 24 h and further incubated for 48 h in a differentiation medium before harvesting and measurement of the reporter gene activity. As shown in Figure 7a , the AchR-a subunit promoter is not activated in RDneo cells. By contrast, we observed a two-to threefold activation of this promoter in RD antisense transfectants. A similar induction was observed in RD Follistatin cells.
Second and more directly, a construct containing the promoter of muscle creatine kinase driving luciferase expression (MCK-luc) was used as a reporter gene for MyoD activity. To evaluate the impact of myostatin on the transcriptional activity of MyoD, we performed transient transfection assay in 10T1/2 cells with MyoD expression vector and the MCK-luciferase reporter in the presence of increasing amounts of myostatin expression vector. As shown in Figure 7b , when transfected into mouse 10T1/2 fibroblasts, the MCK promoter had a low level of activity that increased up to threefold upon cotransfection of MyoD (Figure 7b) . However, in a dose-dependent manner, myostatin induced a marked inhibition of MyoD-dependent activation of MCK-luc. Therefore, we postulate that inhibition on MyoD activity by myostatin could partly explain the lack of differentiation in RD cells.
We next examined the activation of MyoD transcriptional function in RD and Rh30 cells by transfecting the MCK-luciferase reporter alone or together with increasing amounts of follistatin (a myostatin antagonist) expression vector (Figure 7c) . Our results showed an increased MCK-luciferase activity upon follistatin overexpression in both cell lines cultured in differentiation medium. This stimulation is follistatin dose-dependent. Similar results were also observed with transient transfection experiments of the MCK luciferase reporter in RD and Rh30 cells incubated with antimyostatin antibodies (Figure 7d) .
Taken together these results indicate that inhibition of myostatin could restore MyoD activity in RMS cells.
Discussion
In RMS, a human tumor arising from muscle precursors, the muscle program is only partially activated despite the expression of the muscle regulatory protein MyoD (Tapscott et al., 1993) . Therefore, these tumors constitute a model to study the mechanisms responsible for the failure to activate myogenic pathways. The hypothesis that prompted this study was that myostatin, a negative regulator of myogenesis, might contribute to the nonmuscle-differentiating phenotype in RMSs. In this report, we examined RMS cell lines and normal muscle cells for the expression of myostatin. The results reveal that myostatin was overexpressed in RMS cells compared to normal muscle cells and that the failure of RMS cells to differentiation correlates with the persistence of high levels of myostatin. Consistent with these data, we further show that specific downregulation of the myostatin protein restores terminal myogenic differentiation and normal cell cycle withdrawal in RMS cells. Interestingly, we find that, in presence of myostatin, MyoD transcriptional activity is inhibited while inversely inhibition of myostatin restores MyoD activity in RMS cells, raising the possibility that myostatin may impair MyoD function in RMS cells.
Several autocrine loops involved in myogenesis have been associated with RMS proliferation or block of differentiation. The selective inhibition of certain autocrine loops (i.e. insulin-like growth factor IGF, epider- Rltkluc plasmid (25 ng) was included in transfections as internal control for transfection efficiency. At 24 h after transfection antimyostatin antibodies ( þ Ab) or preimmune serum as control (C) were daily added to the cells. At 48 h after transfection, transfected cells were harvested and luciferase activity was measured and corrected with respect to pRL-tk activity. Shown are the mean values of triplicates obtained in two independent experiments. (b) RD and Rh30 cells cultured 3 days in growth medium supplemented with 10% serum were then induced to differentiate in DMEM þ 2% FCS supplemented daily with antimyostatin antibodies ( þ Ab) or preimmune serum as control (C) for 4 days then immunostained with troponin T monoclonal antibody. In all cases, nuclei were stained with Hoechst B2883 dye, Bar: 10-mm. (c) Western blot analysis was carried out for MyoD, myogenin, troponin T, myosin-heavy-chain (MHC), cyclin A and a tubulin as a loading control on protein extracts from differentiated cells cultured for 4 days in a differentiation medium in presence of antimyostatin antibody ( þ Ab) or preimmune serum as control (C) Secretion of myostatin in rhabdomyosarcoma cells S Ricaud et al mal growth factor EGF, basic fibroblast growth factor bFGF) induces growth arrest but does not lead to muscle differentiation, suggesting that this RMS model appears to have a differentiation defect which does not depend solely on proliferative activity (Schweigerer et al., 1987; Shapiro et al., 1994; De Giovanni et al., 1996) . Our study shows that myostatin, a new TGFb family member, acts in an autocrine fashion in RMS-derived RD and Rh30 cells and demonstrates that myostatin is implicated in their differentiation defect. Interestingly, bearing in mind our results, a similar effect of an autocrine loop of TGFb has been described on the differentiation of RD cells (Bouche et al., 2000) . These observations suggest that different members of the TGFb family might act together to restrict differentiation capacity of RMS cells. Given the multiple autocrine circuits observed in RMS, it will be interesting to check whether myostatin signaling can interact with these different growth factor responses. RD and Rh30 cells fail to arrest or differentiate when cultured in differentiation medium. Our results show that the extent of muscle differentiation of these RMS cell lines in vitro could be substantially increased by myostatin blockade. In addition, our results tend to indicate that myostatin is also involved in cell growth control. Interestingly, recent reports have described the ability of myostatin to suppress myoblast cell growth (Thomas et al., 2000; Rios et al., 2001; Taylor et al., 2001) . We have observed a weak stimulation of growth rates for the myostatin antisense RD transfectants, in agreement with the fact that myostatin might play a role in the growth regulation of these cells. This is consistent with the recent observations establishing that myostatin can inhibit both proliferation and differentiation of C2C12 myoblasts (Thomas et al., 2000; Rios et al., 2001 Rios et al., , 2002 Taylor et al., 2001; Langley et al., 2002) .
These prodifferentiation and proliferative effects of myostatin inhibition are of particular interest because cell proliferation and differentiation processes are widely believed to be mutually exclusive in skeletal muscle cells (Olson, 1992) . However, there are a number of examples showing that the relationship between these processes is not so simple. Although growth factors, in general inhibit muscle differentiation (Florini et al., 1991a) , the insulin-like growth factors stimulate both proliferation and differentiation of skeletal muscle cells (Florini et al., 1991b) . Likewise, other growth factors (50, 100 and 250 ng, respectively) . Expression vector without insert was included to normalize DNA in all transfections. RL-tk-luc plasmid (25 ng) was included in transfections as internal control for transfection efficiency. At 24-h post-transfection, cells were grown for 48 h in differentiation medium and then harvested for the luciferase assay. Luciferase activity was measured and corrected with respect to pRL-tk activity. The values shown are means and standard deviations from three independent experiments. (d) RD and Rh30 cells were transiently transfected with MCKluciferase reporter (275 ng). RL-tk-luc plasmid (25 ng) was included in transfections as internal control for transfection efficiency. At 24-h post-transfection, cells were grown for 48 h in differentiation medium daily supplemented with antimyostatin antibodies ( þ Ab) or preimmune serum as control (C) and then harvested for the luciferase assay. Luciferase activity was measured and corrected with respect to pRL-tk activity. Shown are the mean values of triplicates obtained in two independent experiments Secretion of myostatin in rhabdomyosarcoma cells S Ricaud et al such as basic fibroblast growth factor and transforming growth factor b have been shown to negatively regulate muscle differentiation without stimulating proliferation Spizz et al., 1986; Jin et al., 1991) . Interestingly, recent studies indicate that in addition to inhibit proliferation myostatin also inhibits myogenic differentiation in nontransformed muscle cells (Langley et al., 2002) . Inversely, we show here that in proliferative conditions inhibition of myostatin leads to a weak improvement of cell proliferation (using antisense antimyostatin RD transfectants) while in differentiation conditions this inhibition restores normal cell cycle withdrawal and terminal differentiation (demonstrated both in RD transfectants and in RD and Rh30 cells treated with antimyostatin antibody). Recently, it has been shown that the addition of myostatin to proliferative myoblasts induces cell cycle arrest in Gl without inducing their entry into the differentiation pathway (Thomas et al., 2000) . Taken together, these data tend to indicate that myostatin independently controls cell cycle and differentiation. However, additional experiments will be required to determine whether prodifferentiation and proliferative effects of myostatin inhibition are linked or not.
In this report, we showed that the transcriptional activity of MyoD can be downregulated by myostatin, providing a possible explanation for the correlation of elevated myostatin and the poor differentiation ability of RMS cells. This is consistent with the recent report of Langley et al. (2002) suggesting that myostatin inhibits C2C12 myoblast differentiation by repressing MyoD activity. Interestingly, these authors established that, like TGFb signaling, the inhibition of MyoD activity by myostatin signaling is mediated through Smad3. By analogy, it would be interesting to verify whether members of the Smad family could be part of the signaling components that relay the myostatin signal on MyoD in RMS cells.
We present evidences that myostatin acts in a autocrine fashion in RMS cells. Inhibition of myostatin restores the myogenic program in RMS cells whereas it improves to a lesser extent their proliferative capacities. Our results suggest that approaches interfering with this myostatin autocrine loop could have antitumoral applications. Administration of myostatin could antagonize the proliferation of tumoral cells. However, it has been recently reported that systemic administred myostatin causes muscle and fat wasting in adult animals (Zimmers et al., 2002) . Another approach could be based on inhibition of myostatin activity allowing cell cycle withdrawal and induction of the myogenic program in RMS. The feasibility of this approach is supported by two recent reports showing that systemic administration of follistatin or injection of blocking antimyostatin antibodies can interfere with the activity of myostatin in vivo (Bogdanovich et al., 2002; Zimmers et al., 2002) .
Collectively, these data strongly suggest that blocking the action of myostatin by using pharmacological approaches might be an effective way in anti-RMS therapy.
Materials and methods
Cell culture
C2.7 (a subclone of C2 cells) and L6G7 (a subclone of L6 cells) myoblasts were cultured as described .
Clonal human myoblasts were prepared as previously described (Vandromme et al., 2001) . Human RMS cells (RD, Rh30), kindly provided by S Tapscott (Fred Hutchinson Cancer Research Center, Seattle, USA), were maintained in DMEM supplemented with 10% fetal calf serum (FCS, Eurobio). For differentiation, confluent RD, Rh30 and CHM cells were refed with DMEM plus 2% FCS ('differentiation medium') for the indicated times.
To induce RD cell differentiation, TPA treatments were effected as described (Bouche et al., 1993) . To obtain a conditioned medium, cells were grown 48 h in DMEM plus 10% FCS, then the culture medium was collected and used in C2 cell proliferation assay.
Northern blot
Total RNA was prepared using the guanidium thiocyanate procedure and analysed by Northern blot as previously described . Filters were hybridized using the following cDNA probes, which were labeled by random priming: mouse myostatin, mouse myogenin (Edmondson and Olson, 1989 ) and rat GAPDH (Fort et al., 1987) . Radioactivity on the nylon membranes was determined on a Phospholmager analyser (Molecular Dynamics).
Western blot
To detect secreted myostatin, subconfluent cells grown in a proliferation medium were washed with PBS and cultured in serum-free Optimem (Gibco-BRL) for an additional 24 h. Proteins from these supernatants were obtained after precipitation with 10% TCA followed by several washes with À201C acetone. In all, 50 mg total protein (protein concentrations were determined using the BioRad DC kit; BioRad, Ivry/ Seine, France) were transferred onto nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany) .
Cellular protein extracts prepared from proliferating or differentiated Rh30, RD or RD-transfected cells were analysed by Western blot as previously described . The primary antibodies used were: polyclonal anti-myostatin raised against the C-terminal sequence 349-364 of human myostatin (Gonzalez-Cadavid et al., 1998) obtained from Dr M Duclos, INRA, Tours France, diluted at 1/200, MF20 supernatant antimyosin diluted at 1/20, monoclonal antitroponinT (Sigma) diluted at 1/200, monoclonal DMA1A anti-atubulin (Sigma) diluted at 1/2000, polyclonal anti-MyoD (Santa-Cruz Biotechnology Inc.) diluted at 1/400, monoclonal antimyogenin (BD Biosciences) diluted at 1/1000, monoclonal anticyclin A (Novocastra) diluted 1/500. The monoclonal MF20 antibody was obtained from the Developmental Studies Hybridoma Bank (DSHB) developed at the Department of Biological Sciences, Iowa City, IA. After washing, primary antibodies were detected with peroxidase-conjugated secondary antibodies (Amersham, Les Ulis, France) at a dilution of 1/5000 and an ECL kit.
Expression plasmids
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